PT  - JOURNAL ARTICLE
AU  - Peng Du
AU  - Qian Ma
AU  - Jun Xiong
AU  - Yao Wang
AU  - Fan Yang
AU  - Feng Jin
AU  - Yun-Fei Chen
AU  - Zhen-Zhong Shang
AU  - Zhi-Lin Chen
AU  - Xuan Zhou
AU  - Hua-Rong Li
AU  - Lei Zhao
TI  - Corilagin controls post-parasiticide schistosome egg-induced liver fibrosis by inhibiting Stat6 signalling pathway
AID  - 10.1101/340299
DP  - 2018 Jan 01
TA  - bioRxiv
PG  - 340299
4099  - http://biorxiv.org/content/early/2018/06/07/340299.short
4100  - http://biorxiv.org/content/early/2018/06/07/340299.full
AB  - This study aims to explore the effect of Corilagin (Cor) on post-parasiticide schistosome egg-induced hepatic fibrosis through the Stat6 signalling pathway in vitro and in vivo. Cellular and animal models were established and treated by Corilagin. The inhibitory effect of Corilagin was also confirmed in RAW264.7 cells in which Stat6 was overexpressed based on the GV367-Stat6-EGFP lentiviral vector system and in which Stat6 was knock-downed by gene specific siRNAs. As a result, Corilagin prevented increases in the protein level of Phospho-Stat6 (P-Stat6). Both the mRNA and protein levels of the downstream mediators SOCS1, KLF4, and PPARγ/δ were markedly suppressed after Corilagin treatment. Expression of ARG1 and FIZZ1/Retnla, Ym1, TGF-β and PDGF in serum were also inhibited by Corilagin. The pathological changes, area of granulomas of liver sections, and degree of hepatic fibrosis were significantly alleviated in the Corilagin group. The areas of CD68- and CD206-positive cells stained by immunofluorescence were significantly decreased by Corilagin. In conclusion, Corilagin can suppress post-parasiticide schistosome egg-induced hepatic fibrosis by inhibiting the Stat6 signalling pathway and provide a new therapeutic strategy for schistosomiasis liver fibrosis.